Kin Wai Hung, MD
Hematology & Oncology · Hartford, CTNPI 1700129541
Payments from drug & device makers
Across 13 payments — averaging $561.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$7K
- E.r. Squibb & Sons, L.L.C.$44
- Johnson & Johnson$40
- Bayer$20
- AstraZeneca$19
- Pfizer$16
- plus $14 from 1 others
What the payments were for
- Consulting fees$7,08097%
- Travel & lodging$621%
- Food & beverage$1522%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 4 | $7,142 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Johnson & Johnson | 2 | $40 |
| Bayer | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Pfizer | 1 | $16 |
| Hollister Incorporated | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$7,080
How this compares
$7,294 in reported general payments places this provider in the 50th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MekinistTrametinib Dimethyl Sulfoxide | 28 | $466,608 |
| TafinlarDabrafenib Mesylate | 35 | $450,002 |
| ErivedgeVismodegib | 19 | $259,458 |
| Oxycodone Hcl | 20 | $587 |
| Levothyroxine Sodium | 33 | $289 |
| Ondansetron Hcl | 18 | $147 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Hartford
- Jeffrey KamradtHartford$934K
- Jessica ClementHartford$887K
- Zia RahmanHartford$307K
- Madhavi GorusuHartford$207K
- Todd AlekshunHartford$115K
- Adam BoruchovHartford$55K
- Shabnam RehmanHartford$25K
- Amer ZeidanNew Haven$15.5M
- Nataliya UbohaNew Haven$13.3M
- Michael CecchiniNew Haven$7.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.